New combo therapy aims to shrink melanoma before surgery
NCT ID NCT04139902
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving one or two immunotherapy drugs before surgery can shrink advanced melanoma (stage III or IV) that can be removed. About 48 adults with operable melanoma will receive either a single drug (dostarlimab) or a combination (dostarlimab plus cobolimab) before their operation. The main goal is to see how many patients have most of their tumor killed by the treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UPMC Hillman Cancer Center Washington
Washington, Pennsylvania, 15301, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Can interferon keep melanoma from coming back after surgery?
- Pee power: urine bacteria may predict melanoma treatment success
- New Pill-and-Immunotherapy combo aims to shrink melanoma before surgery
- Experimental virus therapy takes on advanced cancers in first human trial
- New pill aims to boost immune attack on Hard-to-Treat cancers